Fig. 6: Trajectories of core CSF and plasma biomarkers in Centimarker. | Nature Communications

Fig. 6: Trajectories of core CSF and plasma biomarkers in Centimarker.

From: Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s disease continuum

Fig. 6: Trajectories of core CSF and plasma biomarkers in Centimarker.

The figure illustrates the trajectories of core biomarkers (%p-tau205, %p-tau217, CSF MTBR-tau243, and plasma eMTBR-tau243) in CSF (solid lines) and plasma (dashed lines) using the Centimarker metric across estimated A Aβ-PET and B tau-PET positivity in years. Centimarker measure was anchored at the mean of cognitively unimpaired amyloid-negative individuals (=0) and amyloid- and tau-positive dementia patients (=100). Highly similar trajectories between CSF and plasma tau biomarkers can be appreciated, with plasma closely following changes in CSF, though showing less of a ceiling effect upon longer disease duration. Note that CSF and plasma trajectories were derived based on their respective cohorts, which had only some overlap in individuals.

Back to article page